Terms: = Prostate cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Prognosis
194 results:
1. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
2. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
[TBL] [Abstract] [Full Text] [Related]
3. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
[TBL] [Abstract] [Full Text] [Related]
4. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract] [Full Text] [Related]
5. Dual targeting of the androgen receptor and PI3K/akt/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
6. Occurrence and Risk Factors for Acute Urinary Retention and Urinary Tract Infection in Patients Undergoing Urinary Drainage after Colorectal Resection.
Song Z; Yu L; Wu Q; Zhang Y
Arch Esp Urol; 2023 Dec; 76(10):772-779. PubMed ID: 38186070
[TBL] [Abstract] [Full Text] [Related]
7. CAV1 and KRT5 are potential targets for prostate cancer.
Guo L; Liu Y; Yang T; Wang G; Liu J; Li S; Liu B; Cai J
Medicine (Baltimore); 2023 Dec; 102(49):e36473. PubMed ID: 38065913
[TBL] [Abstract] [Full Text] [Related]
8. Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer.
Li Z; Quan C; Li W; Ji M
Pathol Res Pract; 2023 Dec; 252():154938. PubMed ID: 37989076
[TBL] [Abstract] [Full Text] [Related]
9. New emerging targets in osteosarcoma therapy: PTEN and PI3K/akt crosstalk in carcinogenesis.
Sadrkhanloo M; Paskeh MDA; Hashemi M; Raesi R; Bahonar A; Nakhaee Z; Entezari M; Beig Goharrizi MAS; Salimimoghadam S; Ren J; Nabavi N; Rashidi M; Dehkhoda F; Taheriazam A; Tan SC; Hushmandi K
Pathol Res Pract; 2023 Nov; 251():154902. PubMed ID: 37922723
[TBL] [Abstract] [Full Text] [Related]
10. PCMT1 regulates the migration, invasion, and apoptosis of prostate cancer through modulating the PI3K/akt/GSK-3β pathway.
Zhong J; Yuan C; Liu L; Du Y; Hui Y; Chen Z; Diao C; Yang R; Liu G; Liu X
Aging (Albany NY); 2023 Oct; 15(20):11654-11671. PubMed ID: 37899170
[TBL] [Abstract] [Full Text] [Related]
11. SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
Wang C; Wang T; Li KJ; Hu LH; Li Y; Yu YZ; Xie T; Zhu S; Fu DJ; Wang Y; Zeng XZ; Liu FP; Chen H; Chen ZS; Feng NH; Liu J; Jiang Y; Zhao SC
Cancer Lett; 2023 Nov; 579():216464. PubMed ID: 37879429
[TBL] [Abstract] [Full Text] [Related]
12. Multiomics and bioinformatics identify differentially expressed effectors in the brain of
Yuan H; Jiang T; Zhang WD; Yang Z; Luo S; Wang X; Zhu X; Qi S; Mahmmod YS; Zhang XX; Yuan ZG
Front Cell Infect Microbiol; 2023; 13():1267629. PubMed ID: 37818043
[TBL] [Abstract] [Full Text] [Related]
13. A Crosstalk Between Castration-Resistant prostate cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/akt-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract] [Full Text] [Related]
14. Mechanism of prognostic marker SPOCK3 affecting malignant progression of prostate cancer and construction of prognostic model.
Luo J; Lai C; Xu X; Shi J; Hu J; Guo K; Mulati Y; Xiao Y; Kong D; Liu C; Xu K
BMC Cancer; 2023 Aug; 23(1):741. PubMed ID: 37563543
[TBL] [Abstract] [Full Text] [Related]
15. PI3K/akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
16. Creation of a Prognostic Model Using Cuproptosis-Associated Long Noncoding RNAs in Hepatocellular Carcinoma.
Yang L; Jia X; Fu Y; Tian J; Liu Y; Lin J
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373132
[TBL] [Abstract] [Full Text] [Related]
17. Analyzing roles of small nucleolar RNA host gene 25 from clinical, molecular target and tumor formation in prostate cancer.
Liu Z; Ke S; Wang Q; Gu X; Zhai G; Shao H; He M; Guo J
Exp Cell Res; 2023 Aug; 429(2):113686. PubMed ID: 37307941
[TBL] [Abstract] [Full Text] [Related]
18. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/akt/mTOR signal pathway.
Azhati B; Reheman A; Dilixiati D; Rexiati M
Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
[TBL] [Abstract] [Full Text] [Related]
19. Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3.
Lin Y; Zhan M; Xu B
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7663-7677. PubMed ID: 37000263
[TBL] [Abstract] [Full Text] [Related]
20. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient prostate cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract] [Full Text] [Related]
[Next]
